The latest IDF Diabetes Atlas (2025) reports that diabetes affects 589 million adults (20-79 years) around the world in 2024, with over 4 in 10 unaware that they have the condition.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.

Waters Corporation (NYSE: WAT) and BD (Becton, Dickinson and Company) (NYSE: BDX) today announced a definitive agreement to combine BD’s Biosciences & Diagnostic Solutions business with Waters, creating an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook. The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion.

Personalis said this week that it has extended its strategic collaboration with Tempus AI to include colorectal cancer (CRC) among the indications covered by their existing, exclusive commercialization agreement.

Claret Bioscience, a pioneer in next-generation sequencing (NGS) library preparation technologies for challenging samples, and Hamilton Company, a global leader in precision laboratory automation, are proud to announce a strategic co-promotion initiative. This collaboration aims to accelerate and simplify workflows for throughput NGS library preparation by delivering validated automation protocols for ClaretBio’s SRSLY® and REALLY™ product lines on Hamilton’s NGS STAR liquid handling platforms.

VieCure Inc., pioneer of an intelligent cancer care ecosystem that democratizes precision oncology for community-based practices, today announced a strategic partnership with Guardant Health to embed Guardant's next-generation sequencing (NGS)-based precision oncology tests into the VieCure Halo Intelligence platform. The integration represents the latest expansion of VieCure's AI-based, scalable, and accessible technology, embedding critical testing required for patient diagnosis and advanced treatment.

The UK government said Thursday that it will align its regulations on high-risk in vitro diagnostic devices that are sold in Great Britain to align with EU specifications and repeal regulations specific to COVID-19 tests.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today a new initiative with NOWDiagnostics (NOWDx), a leader in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, to expand access to rapid syphilis testing. The companies will distribute First to Know® Syphilis Test kits at no cost to select community-based public health organizations across the country.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.

The National Medical Products Administration (NMPA) of China has introduced a series of strategic measures to accelerate the development of new-quality productivity in the high-end medical device sector.

Leinco Technologies, a leading global provider of in vitro diagnostic (IVD) raw materials, today announced the acquisition of BioClin, Inc.’s proprietary antibody clones used as IVD raw materials. This strategic partnership significantly expands Leinco’s portfolio of critical reagents for endocrine hormone research and diagnostic assays.